Apostolos Evangelopoulos
Project Manager at UCL and Senior Research & Innovation Consultant at CBK Sci Con Ltd
As Senior Research & Innovation Consultant of CBK Sci Con, Dr Apostolos Evangelopoulos offers the required expertise for the scientific, administrative and commercial management of CompBioMed. He also offers administrative support to University College London (UCL), which is coordinating the project. He is also Project Manager in a similar European project at UCL.
What is CompBioMed? CompBioMed (Computational BioMedicine) is a European Centre of Excellence focusing on biomedicine, and particularly on the use and development of computational methods for biomedical applications. It supports the modeling and simulating activities in high-performance computing, also known as “supercomputers”, aiming at an in-depth understanding of the physiological and pathological processes of the human body, the prognosis of illnesses, as well as the development of personalized medicine for the making of clinical decisions for patients.
The core of CompΒioΜed consists of three user communities: academics, industrial and clinical researchers. They all wish to build, develop and extend the capabilities of biomedicine, given the increasing power of high-performance computers. Its three main research areas pursued are cardiovascular, molecularly-based and neuro-musculoskeletal medicine.
CompBioMed aims at contributing to the global scientific effort to create a virtual human – that is a complex, multi-scale model that will depict the physiology and the biological processes of the human body with the utmost precision. CompBioMed consists of a consortium of 16 European and two international partners; this includes universities, research centers, and businesses.
In response to the emerging needs due to the COVID-19 pandemic, CompBioMed has joined an international consortium working on urgent coronavirus research. It has used an important part of its research and financial resources to computational research that will improve our understanding about SARS-CoV-2 and COVID-19, accelerating the development of a treatment, including antiviral medicine and vaccines. Since 2016, CompBioMed has been funded by the European Commission’s framework program Horizon 2020, and will continue do to so for at least three more years. Its overall budget is 12.9 million euros.
